- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
RepliCel Announces Two Approvals Necessary for RCS-01 Human Clinical Trial
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP) announced that it has received approval from the Ethics Committee of the Faculty of Medicine Heinrich-Heine Universität Duesseldorf and from the Leibniz-Institut for its Tissue Procurement Authorization (TPA) to conduct a RCS-01 phase 1 human clinical trial. RCS-01 is cell therapy treatment for aged and sun-damaged skin.
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP) announced that it has received approval from the Ethics Committee of the Faculty of Medicine Heinrich-Heine Universität Duesseldorf and from the Leibniz-Institut for its Tissue Procurement Authorization (TPA) to conduct a RCS-01 phase 1 human clinical trial. RCS-01 is cell therapy treatment for aged and sun-damaged skin.
According to the press release:
Ethics Committee approval and TPA are two parts of a three-part Clinical Trial Application (CTA) approval process required to conduct human clinical trials in Germany. The final approval required is from the Paul Ehrlich Institute (PEI), the German regulatory body. If cleared to proceed, the proposed trial will be conducted at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany.
Dr. Rolf Hoffman, Chief Medical Officer, comments:
The market for dermal fillers currently represented almost 6 million procedures and expenditures of almost $2 billion in 2013 according to statistics provided by the American Society of Plastic Surgeons. RCS-01 could disrupt this market by providing patients with a filler comprised of their own fibroblast cells – a much more compelling long-term solution than hyaluronic acid which dissipates in approximately six months.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.